FORM PTO-1449

U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY, DOCKET NO.	SERIAL NO.		
U 013588-9	09/890,990		
APPLI	CANT		
PETER DA	VID DAVIS		
FILING DATE GROUP			
October 22, 2001	1614		

RFF	FRFNO	E DESIGNATION		U.S. PATE		er 22, 200 MENTS	ן ויכ	1614	<u> </u>
EXAMINER INITIAL		DOCUMENT		NAME		CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
		NOIVIDEN	DATE	IVAIV		CLASS	CLASS	APPROI	HIATE
	AA								
	AB							<u> </u>	
	AC						•	<u> </u>	
	AD						•	<u> </u>	
	AE							<u> </u>	
	AF		ļ ,						
	AG							<u> </u>	
	AH							 	
	Al		1					-	
 ·	AJ				 .			-	
	AK			· · ·				<u> </u>	
_			FOREIGN P	ATENT DOCU	MENTS			1	
		DOCUMENT NUMBER DATE		COUNT	COUNTRY CL	CLASS	SUB- CLASS	TRANSL	ATION NO
CA	AL	0641767	3/1995	EP				X	
CA	AM	92/16486	10/1992	WO				X	-
	AN			*		<u> </u>			
	AO						-		
· ,	AP						· · · · · · · · · · · · · · · · · · ·		
		OTHER ART	(Including A	Author, Title, D	ate, Pertin	ent Dates, Et	tc.)	<u> </u>	l .
CA	AR	Ohsumi, Koji, et al. "Novel Combretastatin Analogues Effective against Murine Solid Tumors: Design and Structure-Activity Relationships" J. Med. Chem. (1998) Vol. 41, No. 16 pp 3022-3032							
C-A	AS	Ohsumi, Koji, et al. "Syntheses and Antitumor Activity of Cis-Restricted Combretastatins: 5-Membered Heterocyclic Analogues." Bioorg. Med. Chem. Lett 8 (1998) pp 3153-3158							
C-A	AT	Pettit, George R., et al. "Antineoplastic agents 322. Synthesis of Combretastatin A-4 prodrugs" Anti- Cancer Drug Design (1995) Vol 10, No. 4 pp 299-309							
EXAMINER		ALLAKH DATE CONSIDERED 6.9-03							
EXAMINER:	In	nitial if citation considered	d, whether or	not citation is	in conforn	nance with N	MPEP 609; D	raw line th	rough

EXAMINER: citation if not in conformance and not considered. Include copy of this form with next communication to

applicant.

FORM	PTO-	-1449
-------------	------	-------

U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
U 013588-9	09/890,990
APPLI	CANT
PETER DA	VID DAVIS
FILING DATE	GROUP
O-t-b 22 2001	1614

		F DECICNATION		U.S. PATENT DOCUM	er 22, 200	<u> </u>	1614	
RE	-ERENC	E DESIGNATION		U.S. PATENT DOCUM	T	-	.	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING IF APPROF	
	AA	·						
	AB					· <u>-</u> -		
_	AC							
	AD							
	AE							·
	AF			· · · · · · · · · · · · · · · · · · ·				
	AG						·	
	AH							
	Al	,				_		
	Ą							
	AK			-				_
			FOREIGN P	PATENT DOCUMENTS				
		DOCUMENT				SUB-	TRANSLATION	
		NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO
	AL							
	AM							
	AN							
	AO			· •				
	AP							
	<u></u>	OTHER ART	(Including	Author, Title, Date, Pertin	ent Dates, E	tc.)		
CA	AR	Folkman, Judah, * Clinical Applications of Research on Angiogenesis* Seminars in Medicine of the Beth Israel Hospital, Boston (1995) Vol. 333 No. 26 pp 1757-1763						
CA CA	AS	Dark, Graham G., et al. *Combretastatin A-4, an Agent That Displays Potent and Selective Toxicity toward Tumor Vasculature1* Cancer Research (1997) Vol. 57 pp 1829-1834						
	АТ							
	L	AULAI			ONSIDERED			->

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.